Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Blood (2022) 140 (Supplement 1): 2313–2315.

https://doi.org/10.1182/blood-2022-168983

Published: 2022

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Blood (2018) 132 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2018-99-112178

Published: 2018

Journal Articles

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Blood (2018) 131 (8): 888–898.

https://doi.org/10.1182/blood-2017-08-802470

Published: 2018

Includes: Supplemental data

Journal Articles

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Ian W. Flinn, Susan O’Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey Jones, Jan A. Burger, Nitin Jain, Virginia M. Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven Horwitz

Blood (2018) 131 (8): 877–887.

https://doi.org/10.1182/blood-2017-05-786566

Published: 2018

Includes: Supplemental data

Journal Articles

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Mani Akhtari, Sarah A. Milgrom, Chelsea C. Pinnix, Jay P. Reddy, Wenli Dong, Grace L. Smith, Osama Mawlawi, Zeinab Abou Yehia, Jillian Gunther, Eleanor M. Osborne, Therese Y. Andraos, Christine F. Wogan, Eric Rohren, Naveen Garg, Hubert Chuang, Joseph D. Khoury, Yasuhiro Oki, Michelle Fanale, Bouthaina S. Dabaja

Blood (2018) 131 (1): 84–94.

https://doi.org/10.1182/blood-2017-04-773838

Published: 2018

Journal Articles

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Blood (2017) 130 (Supplement 1): 6.

https://doi.org/10.1182/blood.V130.Suppl_1.6.6

Published: 2017

Journal Articles

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Jason R. Westin, MD, Yasuhiro Oki, MD, Loretta Nastoupil, MD, Luis Fayad, MD, Sattva S. Neelapu, MD, Francesco Turturro, MD, F. B. Hagemeister, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, MD, Ken H. Young, MD PhD, Timothy J. McDonnell, MD PhD, Richard J. Ford, MD PhD, R. Eric Davis, MD

Blood (2017) 130 (Supplement 1): 189.

https://doi.org/10.1182/blood.V130.Suppl_1.189.189

Published: 2017

Journal Articles

Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types

Dai Chihara, MDPhD, Nathan H. Fowler, MD, Yasuhiro Oki, MD, Michelle A. Fanale, MD, Loretta Nastoupil, MD, Jason R. Westin, MD, Luis E. Fayad, Sattva S. Neelapu, MD, Chan Yoon Cheah, MBBS

Blood (2017) 130 (Supplement 1): 4137.

https://doi.org/10.1182/blood.V130.Suppl_1.4137.4137

Published: 2017

Journal Articles

The Role of Radiation Therapy and Risk of Developing Secondary Gastric Cancer in Patients Presenting with Early Stage Gastric Lymphoma

Dai Chihara, MDPhD, Bouthaina S. Dabaja, MD, Yasuhiro Oki, MD, Jason R. Westin, MD, Chan Yoon Cheah, MBBS, Chelsea C Pinnix, MD, Sattva S. Neelapu, MD, Michelle A. Fanale, MD, Nathan H. Fowler, MD, Loretta Nastoupil, MD

Blood (2017) 130 (Supplement 1): 4138.

https://doi.org/10.1182/blood.V130.Suppl_1.4138.4138

Published: 2017

Journal Articles

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Loretta Nastoupil, MD, Jason R. Westin, MD, Nathan H. Fowler, MD, Michelle A. Fanale, MD, Felipe Samaniego, MD, Yasuhiro Oki, MD, Ly Dsouza, PA-C, Chizobam Obi, RN, JingJing Cao, Xiaoyun Cheng, Man Chun John MA, PhD, Wang Zhiqiang, Lei Feng, MS, Shouhao Zhou, R. Eric Davis, MD, Sattva S. Neelapu, MD

Blood (2017) 130 (Supplement 1): 414.

https://doi.org/10.1182/blood.V130.Suppl_1.414.414

Published: 2017

Journal Articles

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4073.

https://doi.org/10.1182/blood.V130.Suppl_1.4073.4073

Published: 2017

Journal Articles

A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas

Paolo Strati, MD, Yasuhiro Oki, MD, Luis E. Fayad, Loretta Nastoupil, MD, Nathan H. Fowler, MD, F. B. Hagemeister, MD, Larry W Kwak, MDPhD, Hun Ju Lee, MD, Michael Wang, MD, Jason R. Westin, MD, Charnelle Ruben, Emily Wesson, NP, Michelle A. Fanale, MD

Blood (2017) 130 (Supplement 1): 4074.

https://doi.org/10.1182/blood.V130.Suppl_1.4074.4074

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Andrei Shustov, MD, Patrick B Johnston, MD PhD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, Guru Reddy, Yasuhiro Oki, MD

Blood (2017) 130 (Supplement 1): 818.

https://doi.org/10.1182/blood.V130.Suppl_1.818.818

Published: 2017

Journal Articles

Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience

Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Ahmad Ghorab, MDMSc, Loretta Nastoupil, MD, Luis E. Fayad, Jeffrey Medeiros, MD, Shimin Hu, Sattva S. Neelapu, MD, Jason R. Westin, MD, Yasuhiro Oki, MD, Michael Wang, MD, Nathan H. Fowler, MD

Blood (2017) 130 (Supplement 1): 2852.

https://doi.org/10.1182/blood.V130.Suppl_1.2852.2852

Published: 2017

Journal Articles

Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study

Yasuhiro Oki, MD, Jasmine Zain, MD, Bradley M. Haverkos, MD MPH, MS, Neil Korman, MD, Lauren Pinter-Brown, MD, Sumana Devata, MD, Rod Ramchandren, MD, Mary Jo Lechowicz, MD, Prajak Barde, MD, Ajit Nair, PhD, Auris Huen, MD

Blood (2017) 130 (Supplement 1): 2791.

https://doi.org/10.1182/blood.V130.Suppl_1.2791.2791

Published: 2017

Journal Articles

Stage I Lymphoma: Difference in Survival Outcome By Site of Involvement

Dai Chihara, MDPhD, Yasuhiro Oki, MD, Michelle A. Fanale, MD, Jason R. Westin, MD, Loretta Nastoupil, MD, Sattva S. Neelapu, MD, Luis E. Fayad, Nathan H. Fowler, MD, Chan Yoon Cheah, MBBS

Blood (2017) 130 (Supplement 1): 1569.

https://doi.org/10.1182/blood.V130.Suppl_1.1569.1569

Published: 2017

Journal Articles

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Daniel J. Landsburg, MD, Rod Ramchandren, MD, Yasuhiro Oki, MD, John M. Pagel, MD PhD, P.J. Lugtenburg, MD PhD, Robert Gharavi, PharmD, Anna Ma, MS, Amir Hafeez, MD, Stefan Klaus Barta, MDMRCP,MS

Blood (2017) 130 (Supplement 1): 1555.

https://doi.org/10.1182/blood.V130.Suppl_1.1555.1555

Published: 2017

Journal Articles

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Blood (2017) 130 (4): 472–477.

https://doi.org/10.1182/blood-2017-02-766121

Published: 2017

NARROW

Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types

The Role of Radiation Therapy and Risk of Developing Secondary Gastric Cancer in Patients Presenting with Early Stage Gastric Lymphoma

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience

Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study

Stage I Lymphoma: Difference in Survival Outcome By Site of Involvement

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only